BIOMAT Database Logo BIOMAT Database Logo

Distribution of FK 506 in plasma lipoproteins in transplant patients. 1991

V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
Department of Pathology, University of Pittsburgh, Pennsylvania 15213.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D016377 Organ Transplantation Transference of an organ between individuals of the same species or between individuals of different species. Grafting, Organ,Transplantation, Organ,Graftings, Organ,Organ Grafting,Organ Graftings,Organ Transplantations,Transplantations, Organ
D016559 Tacrolimus A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. Anhydrous Tacrolimus,FK-506,FK506,FR-900506,Prograf,Prograft,Tacrolimus Anhydrous,Anhydrous, Tacrolimus,FK 506,FR 900506,FR900506,Tacrolimus, Anhydrous

Related Publications

V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression.
February 1990, Transplantation proceedings,
V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients.
February 1995, Transplantation proceedings,
V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
Assay of FK 506 in plasma.
February 1990, Transplantation proceedings,
V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
Infections in adult liver transplant patients under FK 506 immunosuppression.
February 1991, Transplantation proceedings,
V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
Neurotoxicity of FK 506 in liver transplant recipients.
April 1993, Transplantation proceedings,
V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients.
December 1991, Transplantation proceedings,
V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
A combined HPLC-ELISA evaluation of FK 506 in transplant patients.
December 1991, Transplantation proceedings,
V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group.
January 1994, Transplant international : official journal of the European Society for Organ Transplantation,
V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
FK 506 inhibits the development of transplant arteriosclerosis.
December 1991, Transplantation proceedings,
V Warty, and R Venkataramanan, and P Zendehrouh, and T McKaveney, and J Chao, and S Todo, and T Starzl
Clinical study of FK 506 in renal transplant recipients.
November 2000, Transplantation proceedings,
Copied contents to your clipboard!